Heart failure with preserved ejection fraction: New approaches to diagnosis and management

The majority of older patients who develop heart failure (HF), particularly older women, have a preserved left ventricular ejection fraction (HFpEF). Patients with HFpEF have severe symptoms of exercise intolerance, poor quality‐of‐life, frequent hospitalizations, and increased mortality. The preval...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cardiology (Mahwah, N.J.) Jg. 43; H. 2; S. 145 - 155
Hauptverfasser: Upadhya, Bharathi, Kitzman, Dalane W.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New York Wiley Periodicals, Inc 01.02.2020
John Wiley & Sons, Inc
Schlagworte:
Age Factors
Aged
Aged, 80 and over
Aging
Biomarkers
Cardiology
Cell adhesion & migration
Chronic obstructive pulmonary disease
Clinical outcomes
Clinical trials
Comorbidity
Drug development
Ejection fraction
Exercise
Female
geriatric syndrome
Heart failure
Heart Failure - diagnosis
Heart Failure - epidemiology
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Hypertension
Inflammation
Kinases
Male
Mortality
Musculoskeletal system
Obesity
Older people
Physical fitness
Predictive Value of Tests
preserved ejection fraction
Quality of Life
Recovery of Function
Review
Reviews
Risk Assessment
Risk Factors
Stroke Volume
therapy
Time Factors
Treatment Outcome
Ultrasonic imaging
Ventricular Function, Left
preserved ejection fraction
heart failure
geriatric syndrome
aging
therapy
ISSN:0160-9289, 1932-8737, 1932-8737
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The majority of older patients who develop heart failure (HF), particularly older women, have a preserved left ventricular ejection fraction (HFpEF). Patients with HFpEF have severe symptoms of exercise intolerance, poor quality‐of‐life, frequent hospitalizations, and increased mortality. The prevalence of HFpEF is increasing and its prognosis is worsening. However, despite its importance, our understanding of the pathophysiology of HFpEF is incomplete, and drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Originally viewed as a disorder due solely to abnormalities in left ventricular (LV) diastolic function, our understanding has evolved such that HFpEF is now understood as a systemic syndrome, involving multiple organ systems, likely triggered by inflammation and with an important contribution of aging, lifestyle factors, genetic predisposition, and multiple‐comorbidities, features that are typical of a geriatric syndrome. HFpEF is usually progressive due to complex mechanisms of systemic and cardiac adaptation that vary over time, particularly with aging. In this review, we examine evolving data regarding HFpEF that may help explain past challenges and provide future directions to care patients with this highly prevalent, heterogeneous clinical syndrome.
Bibliographie:Funding information
national institue of health, Grant/Award Numbers: R01AG045551, R01AG18915
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Funding information national institue of health, Grant/Award Numbers: R01AG045551, R01AG18915
ISSN:0160-9289
1932-8737
1932-8737
DOI:10.1002/clc.23321